Publications by authors named "Bruce E Johnson"

99Publications

Tumor volume dynamics and tumor growth rate in -rearranged advanced non-small-cell lung cancer treated with crizotinib.

Eur J Radiol Open 2020 28;7:100210. Epub 2020 Jan 28.

Department of Medical Oncology and Department of Medicine, Dana-Farber Cancer Institute and Brigham and Women's Hospital, 450 Brookline Ave., Boston, MA, 02215, USA.

View Article and Find Full Text PDF
January 2020

MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium.

J Thorac Oncol 2019 09 20;14(9):1666-1671. Epub 2019 Jun 20.

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Weill Cornell Medical College, New York, New York.

View Article and Find Full Text PDF
September 2019

Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer.

J Immunother Cancer 2019 03 28;7(1):87. Epub 2019 Mar 28.

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA, 02215, USA.

View Article and Find Full Text PDF
March 2019

M1b Disease in the 8th Edition of TNM Staging of Lung Cancer: Pattern of Single Extrathoracic Metastasis and Clinical Outcome.

Oncologist 2019 08 29;24(8):e749-e754. Epub 2019 Jan 29.

Department of Radiology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts, USA

View Article and Find Full Text PDF
August 2019

Automated image analysis tool for tumor volume growth rate to guide precision cancer therapy: EGFR-mutant non-small-cell lung cancer as a paradigm.

Eur J Radiol 2018 Dec 23;109:68-76. Epub 2018 Oct 23.

Department of Medical Oncology and Department of Medicine, Dana-Farber Cancer Institute and Brigham and Women's Hospital, 450 Brookline Ave., Boston, MA 02215, USA.

View Article and Find Full Text PDF
December 2018

2018 ASCO Presidential Address: "Delivering Discoveries: Expanding the Reach of Precision Medicine".

Authors:
Bruce E Johnson

J Clin Oncol 2018 10 30;36(29):2899-2903. Epub 2018 Aug 30.

Bruce E. Johnson, Dana-Farber Cancer Institute, Boston, MA.

View Article and Find Full Text PDF
October 2018

A Phase I Trial of Surgical Resection and Intraoperative Hyperthermic Cisplatin and Gemcitabine for Pleural Mesothelioma.

J Thorac Oncol 2018 09 9;13(9):1400-1409. Epub 2018 May 9.

Department of Surgery, Division of General Thoracic Surgery, Baylor College of Medicine, Houston, Texas. Electronic address:

View Article and Find Full Text PDF
September 2018

BRAF Adds an Additional Piece of the Puzzle to Precision Oncology-Based Treatment Strategies in Lung Cancer.

Arch Pathol Lab Med 2018 07 12;142(7):796-797. Epub 2018 Apr 12.

From the Department of Medical Oncology, Gustave Roussy, Villejuif, France (Dr Planchard); and the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, (Dr Johnson).

View Article and Find Full Text PDF
July 2018

HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium.

Cancer 2017 Nov 25;123(21):4099-4105. Epub 2017 Jul 25.

Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.

View Article and Find Full Text PDF
November 2017

Guideline: An expert panel found that calcium intake is safe from a cardiovascular perspective.

Ann Intern Med 2017 02;166(4):JC16

Virginia Tech Carilion School of MedicineRoanoke, Virginia, USA.

View Article and Find Full Text PDF
February 2017

Co-clinical quantitative tumor volume imaging in ALK-rearranged NSCLC treated with crizotinib.

Eur J Radiol 2017 Mar 26;88:15-20. Epub 2016 Dec 26.

Department of Medical Oncology and Department of Medicine Dana-Farber Cancer Institute and Brigham and Women's Hospital 450 Brookline Ave., Boston MA, 02215, USA.

View Article and Find Full Text PDF
March 2017

Divide and Conquer to Treat Lung Cancer.

Authors:
Bruce E Johnson

N Engl J Med 2016 11 8;375(19):1892-1893. Epub 2016 Oct 8.

From the Department of Medical Oncology, Dana-Farber Cancer Institute, and the Department of Medicine, Brigham and Women's Hospital - both in Boston.

View Article and Find Full Text PDF
November 2016

Emerging gene mutation targets in lung cancer.

Authors:
Bruce E Johnson

Clin Adv Hematol Oncol 2015 Dec;13(12):812-4

Harvard Medical School, Boston, Massachusetts.

View Article and Find Full Text PDF
December 2015

Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib.

Acad Radiol 2016 Mar 8;23(3):329-36. Epub 2016 Jan 8.

Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

View Article and Find Full Text PDF
March 2016

Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs.

J Thorac Oncol 2016 Apr 25;11(4):556-65. Epub 2015 Dec 25.

Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Brigham and Women's Hospital, Boston, Massachusetts; Department of Medicine, Harvard Medical School, Boston, Massachusetts. Electronic address:

View Article and Find Full Text PDF
April 2016

A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer.

Oncotarget 2015 Feb;6(6):4527-36

Department of Neurosciences, Translational Neuro-Oncology Laboratories, Moores UCSD Cancer Center, University of California, San Diego, La Jolla CA, USA.

View Article and Find Full Text PDF
February 2015

Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors.

Lung Cancer 2014 Nov 27;86(2):241-6. Epub 2014 Aug 27.

Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, United States. Electronic address:

View Article and Find Full Text PDF
November 2014

Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of advanced non-small-cell lung cancer (ATLAS).

J Thorac Oncol 2014 Sep;9(9):1411-7

*University of California Los Angeles, Los Angeles, CA; †Kaiser Permanente Northern CA, Antioch, CA; ‡Sarah Cannon Research Institute, Nashville, TN; §Northwest Medical Specialties, Tacoma, WA; ‖Sibley Memorial Hospital, Washington, DC; ¶Integrated Community Oncology Network, Jacksonville, FL; #The Mark H. Zangmeister Center, Columbus, OH; **Florida Cancer Specialists, Bonita Springs, FL; ††Arch Medical Services Inc., The Center for Cancer Care and Research, Saint Louis, MO; ‡‡National Taiwan University, Taipei, Taiwan; §§F. Hoffmann-La Roche Ltd., Basel, Switzerland; ‖‖Genentech Inc., South San Francisco, CA; ¶¶Weill Cornell Medical College and Thoracic Oncology Service, New York, NY; and ##Dana-Farber Cancer Institute, Boston, MA.

View Article and Find Full Text PDF
September 2014

Realizing the potential of plasma genotyping in an age of genotype-directed therapies.

J Natl Cancer Inst 2014 Aug 8;106(8). Epub 2014 Aug 8.

Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA (JJL, GRO, CPP, BEJ), Memorial Sloan-Kettering Cancer Center, New York, NY (DBS), University of Colorado Cancer Center, Denver, CO (DRC); The University of Texas MD Anderson Cancer Center, Houston, TX (JVH).

View Article and Find Full Text PDF
August 2014

Evaluation of statistical designs in phase I expansion cohorts: the Dana-Farber/Harvard Cancer Center experience.

J Natl Cancer Inst 2014 Jul 24;106(7). Epub 2014 Jun 24.

Affiliations of authors: Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA (SED); Department of Medical Oncology and Department of Medicine, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA (GIS, BEJ); Department of Hematology and Oncology (JWC) and Department of Medicine (JWC), Massachusetts General Hospital, Boston, MA.

View Article and Find Full Text PDF
July 2014

Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer.

Int J Radiat Oncol Biol Phys 2014 Jul 24;89(4):880-7. Epub 2014 May 24.

Dana-Farber Cancer Institute, Boston, Massachusetts; Brigham and Women's Hospital, Boston, Massachusetts. Electronic address:

View Article and Find Full Text PDF
July 2014

State of the art: Response assessment in lung cancer in the era of genomic medicine.

Radiology 2014 Apr;271(1):6-27

From the Departments of Imaging (M.N.) and Medical Oncology (B.E.J.), Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215; Departments of Radiology (M.N., H.H.) and Medicine (B.E.J.), Brigham and Women's Hospital, Boston, Mass; and Department of Radiology, Massachusetts General Hospital, Boston, Mass (T.C.M.).

View Article and Find Full Text PDF
April 2014

Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung.

J Thorac Oncol 2013 Nov;8(11):1434-7

*Massachusetts General Hospital Cancer Center, Boston, Massachusetts; †Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts; ‡Department of Pathology and Center for Advanced Molecular Diagnostics, Brigham and Women's Hospital, Boston, Massachusetts; and §Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article and Find Full Text PDF
November 2013

ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer.

J Clin Oncol 2013 Nov 7;31(31):3926-34. Epub 2013 Oct 7.

Bruce E. Johnson, Dana-Farber Cancer Institute, Boston, MA; Fairooz Kabbinavar, University of California Los Angeles, Translational Oncology Research International, Los Angeles; Louis Fehrenbacher, Kaiser Permanente Northern California, Vallejo; Chin-Yu Lin and Chris Bowden, Genentech, South San Francisco; Jonathan Polikoff, Southern California Permanente Medical Group, San Diego, CA; John Hainsworth, Sarah Cannon Research Institute, Nashville, TN; Saifuddin Kasubhai, Northwest Medical Specialties, Tacoma, WA; Bruce Kressel, Sibley Memorial Hospital, Washington, DC; Thomas Marsland, Integrated Community Oncology Network, Orange Park; Mark Rubin, Florida Cancer Specialists, Fort Myers, FL; Taral Patel, The Mark H. Zangmeister Center, Columbus, OH; Leonard White, Arch Medical Services, The Center for Cancer Care and Research, Saint Louis, MO; Vincent Miller, Weill Cornell Medical College and Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY; and James Chih-Hsin Yang, National Taiwan University, Taipei, Taiwan.

View Article and Find Full Text PDF
November 2013

Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization.

Cancer Res 2013 Nov 24;73(22):6770-9. Epub 2013 Sep 24.

Authors' Affiliations: Departments of Medical Oncology and Cancer Biology; Center for Cancer Genome Discovery, Lowe Center for Thoracic Oncology, and Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute; Departments of Medicine, Brigham and Women's Hospital; Departments of Biological Chemistry and Molecular Pharmacology and Pathology, Harvard Medical School, Boston, Massachusetts; Samsung Genome Institute, Samsung Medical Center, Seoul, Republic of Korea; and The Broad Institute of Harvard and MIT, Cambridge, Massachusetts.

View Article and Find Full Text PDF
November 2013

The impact of genomic changes on treatment of lung cancer.

Am J Respir Crit Care Med 2013 Oct;188(7):770-5

1 Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; and.

View Article and Find Full Text PDF
October 2013

Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.

Clin Cancer Res 2013 Aug 5;19(16):4532-40. Epub 2013 Jul 5.

Department of Medical Oncology, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.

View Article and Find Full Text PDF
August 2013

RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0.

AJR Am J Roentgenol 2013 Jul;201(1):W64-71

Department of Imaging Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave., Boston MA 02215, USA.

View Article and Find Full Text PDF
July 2013

The introduction of systematic genomic testing for patients with non-small-cell lung cancer.

J Thorac Oncol 2012 Dec;7(12):1767-1774

Department of Medical Oncology, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts; Department of Medicine, Harvard Medical School, Boston, Massachusetts.

View Article and Find Full Text PDF
December 2012

Chapter 9: The MGH-HMS lung cancer policy model: tobacco control versus screening.

Risk Anal 2012 Jul;32 Suppl 1:S117-24

Institute for Technology Assessment, Massachusetts General Hospital, 101 Merrimac Street, Boston, MA 02114, USA.

View Article and Find Full Text PDF
July 2012

Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab.

Cancer Imaging 2012 Jun 29;12:225-35. Epub 2012 Jun 29.

Department of Radiology, Dana-Farber Cancer Institute and Brigham and Womens Hospital, Boston, MA 02215-5450, USA.

View Article and Find Full Text PDF
June 2012

Adjuvant chemotherapy for surgically resected non-small cell lung cancer.

J Thorac Cardiovasc Surg 2012 Sep 13;144(3):S39-42. Epub 2012 Apr 13.

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana Building 1234, Boston, MA 02215, USA.

View Article and Find Full Text PDF
September 2012

Patient-reported receipt of and interest in smoking-cessation interventions after a diagnosis of cancer.

Cancer 2011 Jul 10;117(13):2961-9. Epub 2011 Jan 10.

Phyllis F. Cantor Center for Research in Nursing and Patient Care Services, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

View Article and Find Full Text PDF
July 2011

Imaging of lung cancer in the era of molecular medicine.

Acad Radiol 2011 Apr 28;18(4):424-36. Epub 2011 Jan 28.

Department of Imaging, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

View Article and Find Full Text PDF
April 2011

Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib.

Clin Cancer Res 2010 Dec 28;16(23):5873-82. Epub 2010 Oct 28.

Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.

View Article and Find Full Text PDF
December 2010

Haplotypes of estrogen receptor-beta and risk of non-small cell lung cancer in women.

Lung Cancer 2011 Mar 23;71(3):258-63. Epub 2010 Jul 23.

Department of Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA.

View Article and Find Full Text PDF
March 2011